
Zynex Inc (ZYXI) Stock Forecast & Price Target
Zynex Inc (ZYXI) Analyst Ratings
Bulls say
Zynex Inc. reported a 16% year-over-year growth in orders for Fiscal Year 2024, indicating a robust demand for its electrotherapy and pain management products. The company's focus on enhancing revenue per sales representative to $1 million, alongside positive clinical study results for its laser-based system, positions Zynex strongly within the medical device sector as a leader in non-opioid pain management solutions. Additionally, a projected annual savings of approximately $35 million from expense reductions in the second half of 2025 and the first quarter of 2025 further enhances the company's financial outlook, potentially leading to increased profitability and market share growth.
Bears say
Zynex Inc has indicated a significant downturn in its financial outlook, with projected Q1 2025 sales of at least $30 million, highlighting a decline of 37% year-over-year and a 35% sequential decrease. The company's Q4 2024 total revenue was reported at $46 million, reflecting a 3% decline year-over-year and a notable shortfall against earlier projections. Furthermore, Zynex's earnings report showed an EPS loss of $0.30, compounded by reduced sales expectations for 2025, which are now modeled at $140 million, representing a 28% decrease year-over-year, thus underscoring concerns about operational visibility and ongoing business challenges.
This aggregate rating is based on analysts' research of Zynex Inc and is not a guaranteed prediction by Public.com or investment advice.
Zynex Inc (ZYXI) Analyst Forecast & Price Prediction
Start investing in Zynex Inc (ZYXI)
Order type
Buy in
Order amount
Est. shares
0 shares